The researchers will present their findings
"In preliminary results in 40 patients, the test could differentiate between Alzheimer's disease and non-Alzheimer's disease with 100 percent sensitivity and 80.6 percent specificity, meaning that all people with the disease tested positive and most of the people without the disease tested negative. The optical imaging exam appears to detect changes that occur 15-20 years before clinical diagnosis. It's a practical exam that could allow testing of new therapies at an earlier stage, increasing our chances of altering the course of Alzheimer's disease," said
Frost, first author of the AAIC 2014 abstract, will make the oral presentation. He said 120 participants of a full study of 200 had completed testing.
"PET scans require the use of radioactive tracers, and cerebrospinal fluid analysis requires that patients undergo invasive and often painful lumbar punctures, but neither approach is quite feasible, especially for patients in the earlier stages of disease," he said. Positron emission tomography, or PET, is the current diagnostic standard.
"The retina, unlike other structures of the eye, is part of the central nervous system, sharing many characteristics of the brain. A few years ago, we discovered at Cedars-Sinai that the plaques associated with Alzheimer's disease occur not only in the brain but also in the retina. By 'staining' the plaque with curcumin, a component of the common spice turmeric, we could detect it in the retina even before it began to accumulate in the brain. The device we developed enables us to look through the eye - just as an ophthalmologist looks through the eye to diagnose retinal disease - and see these changes."
This clinical trial was designed to enable researchers to correlate retinal plaque detected by optical imaging with brain plaque detected by PET scans. Studies involved patients diagnosed with Alzheimer's, a group with mild cognitive impairment and a group of people with no evidence of brain abnormality.
The retinal beta-amyloid plaque findings and optical imaging technology began at Cedars-Sinai with studies in live rodents and the post-mortem investigation of human retinas of people who had died with Alzheimer's. Maya Koronyo-Hamaoui, PhD, assistant professor of neurosurgery in the
"This large double-blind clinical trial appears to validate our novel human retinal amyloid imaging approach using curcumin labeling. It further demonstrates significant correlation with brain amyloid burden, thereby predicting accumulation of plaques in the brain through the retina," said Koronyo-Hamaoui, a faculty principal investigator and head of the
Keywords for this news article include: Alzheimer Disease, Amyloid, Brain Diseases,
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Most Popular Stories
- Toxic Algae Threatens Florida Fishing, Tourism
- Hispanic Groups Lead Voter Registration Drive
- Eva Mendes Gives Birth to a Baby Girl
- Fed Signals It Will Keep Key Rate at Record Low
- Stocks Rise Before Fed Statement
- Occupy Wall Street Buys Up Student Debt
- FedEx Adding 50,000 Holiday Jobs
- Plus-Size iPhones Live Up to The Hype
- Cool Features on Today's New iOS 8
- Kohl's Hiring 67,000 for the Holidays